File Download
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-34250781200
- PMID: 16774014
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Determinants of patient survival in systemic lupus erythematosus--focusing on lupus nephritis.
Title | Determinants of patient survival in systemic lupus erythematosus--focusing on lupus nephritis. |
---|---|
Authors | |
Keywords | Cyclophosphamide Ethnicity Lupus nephritis Mycophenolate mofetil Survival |
Issue Date | 2006 |
Publisher | International Society on Hypertension in Blacks. The Journal's web site is located at http://www.ishib.org/ED_index.asp |
Citation | Ethnicity & Disease., 2006, v. 16 n. 2 Suppl 2, p. S2-66-S2-69 How to Cite? |
Abstract | INTRODUCTION: Systemic lupus erythematosus is more prevalent among Asians, African Americans, and Hispanics than in Caucasians. Progress in its management over the past few decades has resulted in improved patient survival, although a considerable proportion of patients are still afflicted with long-term illnesses such as chronic renal failure secondary to lupus nephritis. METHODS AND RESULTS: This is a review of the factors that affect the survival of patients with systemic lupus erythematosus, including discussion of the measures that can further improve the clinical outcomes and prevent long-term complications. Recent advances in the treatment of severe lupus nephritis are emphasized, especially with regard to the minimization of treatment-related adverse events. CONCLUSIONS: While the prognosis of patients with severe lupus manifestations continues to improve, prevention of relapse remains a clinical challenge. Concomitant attention to health economics and sociopolitical issues is required to ensure that all patients can benefit from scientific progress in the understanding and treatment of severe lupus erythematosus. |
Persistent Identifier | http://hdl.handle.net/10722/162998 |
ISSN | 2023 Impact Factor: 3.4 2023 SCImago Journal Rankings: 1.062 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, TM | en_US |
dc.date.accessioned | 2012-09-05T05:26:23Z | - |
dc.date.available | 2012-09-05T05:26:23Z | - |
dc.date.issued | 2006 | en_US |
dc.identifier.citation | Ethnicity & Disease., 2006, v. 16 n. 2 Suppl 2, p. S2-66-S2-69 | en_US |
dc.identifier.issn | 1049-510X | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/162998 | - |
dc.description.abstract | INTRODUCTION: Systemic lupus erythematosus is more prevalent among Asians, African Americans, and Hispanics than in Caucasians. Progress in its management over the past few decades has resulted in improved patient survival, although a considerable proportion of patients are still afflicted with long-term illnesses such as chronic renal failure secondary to lupus nephritis. METHODS AND RESULTS: This is a review of the factors that affect the survival of patients with systemic lupus erythematosus, including discussion of the measures that can further improve the clinical outcomes and prevent long-term complications. Recent advances in the treatment of severe lupus nephritis are emphasized, especially with regard to the minimization of treatment-related adverse events. CONCLUSIONS: While the prognosis of patients with severe lupus manifestations continues to improve, prevention of relapse remains a clinical challenge. Concomitant attention to health economics and sociopolitical issues is required to ensure that all patients can benefit from scientific progress in the understanding and treatment of severe lupus erythematosus. | en_US |
dc.language | eng | en_US |
dc.publisher | International Society on Hypertension in Blacks. The Journal's web site is located at http://www.ishib.org/ED_index.asp | en_US |
dc.relation.ispartof | Ethnicity & disease. | en_US |
dc.subject | Cyclophosphamide | - |
dc.subject | Ethnicity | - |
dc.subject | Lupus nephritis | - |
dc.subject | Mycophenolate mofetil | - |
dc.subject | Survival | - |
dc.subject.mesh | Adrenal Cortex Hormones - Administration & Dosage | en_US |
dc.subject.mesh | Cyclophosphamide - Administration & Dosage | en_US |
dc.subject.mesh | Drug Therapy, Combination | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunosuppressive Agents - Administration & Dosage | en_US |
dc.subject.mesh | Lupus Nephritis - Drug Therapy - Ethnology - Mortality | en_US |
dc.subject.mesh | Mycophenolic Acid - Administration & Dosage - Analogs & Derivatives | en_US |
dc.subject.mesh | Risk Factors | en_US |
dc.subject.mesh | United States - Epidemiology | en_US |
dc.title | Determinants of patient survival in systemic lupus erythematosus--focusing on lupus nephritis. | en_US |
dc.type | Article | en_US |
dc.identifier.email | Chan, TM:dtmchan@hku.hk | en_US |
dc.identifier.authority | Chan, TM=rp00394 | en_US |
dc.description.nature | link_to_OA_fulltext | en_US |
dc.identifier.pmid | 16774014 | en_US |
dc.identifier.scopus | eid_2-s2.0-34250781200 | en_US |
dc.identifier.hkuros | 117902 | - |
dc.identifier.volume | 16 | en_US |
dc.identifier.issue | 2 Suppl 2 | en_US |
dc.identifier.spage | S2-66 | en_US |
dc.identifier.epage | s2-69 | en_US |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Chan, TM=7402687700 | en_US |
dc.customcontrol.immutable | jt 130423 | - |
dc.identifier.issnl | 1049-510X | - |